Results 111 to 120 of about 577,319 (266)

Clinical Outcomes of SEEG‐Guided Radiofrequency Thermocoagulation in Children With Focal Drug‐Resistant Epilepsy: A Multicenter Real‐World Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Stereoelectroencephalography‐guided radiofrequency thermocoagulation (SEEG‐RFTC) has emerged as a safe and effective minimally invasive treatment for children with drug‐resistant focal epilepsy. Although evidence from real‐world studies remains limited, numerous pediatric cases have demonstrated promising outcomes. This retrospective
Weitao Chen, Stéphane Jean, Weihong Liu, Yihai Dai, Xinrong Fang, Xiaoqiang Wei, Shan Chen, Shiwei Song   +7 more
wiley   +1 more source

Imaging and plasma biomarkers for pathological accumulation in Down syndrome. [PDF]

Brain
Wisch JK, Jiao Z, Kennedy JT, Cohen AD, Schlachetzki Z, Petersen M, Handen BL, Christian BT, Mapstone M, Rosas HD, Lai F, Lee JH, Krinsky-McHale SJ, Schmitt FA, Harp JP, Hom C, Lott IT, Hartley S, Zaman S, Ptomey L, Burns JM, Tudorascu D, Ibanez L, Rafii MS, Head E, Ances BM.   +25 more
europepmc   +1 more source

Relationship Between Neurologic Symptoms and Signs and FMR1 Genotype in Premutation Carriers

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background and Objectives Fragile X‐associated Tremor/Ataxia Syndrome (FXTAS) is the most severe late‐onset condition caused by a premutation in the FMR1 gene, characterized by expanded CGG triplet repeats of 55–200. Clinical presentations of FXTAS, including gait ataxia, kinetic tremor, cognitive decline, and rare Parkinsonism, are linked to ...
Flora Tassone, Freddy Chafota, Miguel E. Rentería, Randi J. Hagerman, Ellery Santos, Anna Atkinson, Nicholas G. Martin, Elsdon Storey, Danuta Z. Loesch   +8 more
wiley   +1 more source

Lifestyle intervention and cognitive outcomes in Down syndrome: a horizon 21 European Down syndrome consortium scoping review. [PDF]

J Neurodev Disord
McGlinchey E, Pape S, Zaman SH, Eustace-Cook J, Stockbauer A, Baldimtsi E, Langballe EM, Larsen FK, Sandkühler K, Ivain P, Rebillat AS, Ecrement P, McCarron M, Benejam B, Khoo WM, Fortea J, Levin J, Öhman F, Granholm-Bentley AC, Strydom A, Nübling G.   +20 more
europepmc   +1 more source

[18F]Fluorodeprenyl‐D2 PET as a Tool to Monitor Disease Activity in GAD65‐Ab Autoimmune Encephalitis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate [18F]fluorodeprenyl‐D2 ([18F]F‐DED) positron‐emission tomography (PET) imaging as a biomarker of disease activity in autoimmune encephalitis (AIE) associated with glutamic acid decarboxylase 65 (GAD65) antibodies. Methods [18F]F‐DED PET was performed in 25 GAD65‐AIE patients and 8 controls using dynamic (0–60 min) and ...
Julia S. Dorneich, Jonathan A. Gernert, Hanna Zimmermann, Lisa Tagnin, Marianthi Zeinaki, Laura Sanzo, Letizia Vogler, Elisabeth Kaufmann, Justina Dargvainiene, Frank Leypoldt, Gérard N. Bischof, Robert Perneczky, Boris‐Stephan Rauchmann, Simon Lindner, Günter U. Höglinger, Rudolf A. Werner, Martin Kerschensteiner, Tania Kümpfel, Matthias Brendel, Franziska S. Thaler   +19 more
wiley   +1 more source

GAD65 Antibody ELISA With Extended Reportable Range: Validation and Guidance for Neurological Practice

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To (1) validate GAD65‐ELISA detection and quantification for type 1 diabetes mellitus and autoimmune neurological diagnoses, (2) correlate ELISA results (reference range < 5 IU/mL) with established radioimmunoprecipitation assay (RIA; ≤ 0.02 nmol/L), and (3) define ELISA clinical utility and pitfalls.
Andrew McKeon, Dana Olofson, Diana Anissian, Divyanshu Dubey, Eoin P. Flanagan, Max C. Herman, Sarosh R. Irani, Daniel H. Lachance, Maria A. Willrich, Sean Pittock, John R. Mills, Anastasia Zekeridou   +11 more
wiley   +1 more source

A challenging case of Down syndrome regression disorder. [PDF]

Arq Neuropsiquiatr
Monteiro LKM, Santos AP, Lima HSM, Campos RSM, Gandara JMB, Araújo LC, Barbosa BJAP.   +6 more
europepmc   +1 more source

MYCOPLASMA AND DOWN'S SYNDROME [PDF]

The Lancet, 1967
Vries, G.F. de, Vogelzang, A.A.
openaire   +2 more sources

RNA Sequencing Resolves Cryptic Pathogenic Variants in Mitochondrial Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Mitochondrial diseases are the most common inherited metabolic disorders, characterized by pronounced clinical and genetic heterogeneity that complicates molecular diagnosis. Although DNA‐based sequencing approaches have become standard in genetic testing, up to half of patients remain without a definitive diagnosis.
Zhimei Liu, Xin Duan, Fatemeh Peymani, Jia Wang, Chengjia Bao, Chaolong Xu, Ying Zou, Zixuan Zhang, Yunxi Zhang, Tongyue Li, Martin Pavlov, Junling Wang, Minhan Song, Tianyu Song, Xiaodi Han, Mingxi Sun, Danmin Shen, Ruoyu Duan, Huafang Jiang, Manting Xu, Holger Prokisch, Fang Fang   +21 more
wiley   +1 more source

The tau biomarker cascade is condensed in Down syndrome compared with sporadic Alzheimer's disease. [PDF]

Brain
Zammit MD, Bruzzone H, Cody KA, Morse J, Wilson R, Bettcher BT, McLachlan MJ, McVea AK, DiFilippo AH, Carey FJ, Janelidze S, Hansson O, Price JC, Laymon CM, Minhas DS, Luo W, Rosas HD, Lai F, Lee JH, Lao PJ, Ances BM, Krinsky-McHale SJ, Hom CL, Hartley SL, Zaman SH, Johnson SC, Cohen AD, Head E, Mapstone ME, Handen BL, Christian BT, Tudorascu DL, Langhough RE, Betthauser TJ, Alzheimer Biomarker Consortium–Down Syndrome .   +34 more
europepmc   +1 more source